All Posts

Last week the House of Representatives unanimously passed the Mikaela Naylon Give Kids a Chance Act. This legislation will  give the FDA authority to direct pediatric cancer trials for combination drugs, reauthorize the Rare Pediatric Priority Review Voucher, and provide more funds for NIH pediatric drug studies. This legislation is an important step forward in the fight to close gaps in pediatric cancer research and develop more effective, less toxic medicine.  We applaud th

In this short State of the Science  spotlight, Dr. Keren Sturtz , Executive Senior Director at Pfizer Oncology Early Clinical Development, shares why breakthroughs in pediatric brain cancer depend on one thing above all: everyone working together. Dr. Sturtz explains why rare pediatric brain tumors require creative thinkers, strong research infrastructure, and the combined efforts of academic centers, biotech innovators, big pharma, government funding—and philanthropy. She hi

In the ever-evolving world of scientific discovery, breakthroughs often capture headlines and spark public imagination. But behind these monumental achievements are dedicated scientists, tirelessly working to push the boundaries of knowledge.

Understanding Juvenile Pilocytic Astrocytoma (JPA): 5 Key Facts